Abivax S.A.
Narrative signal
Abivax S.A.’s revenue growth stands at 133.5% for Dec 2024. Year-over-year, the metric shifted by +132.7 pts, translating into a +16,005.93% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
Valuation Signals
Track how the market prices earnings, book value, and operating cash flow for rapid context on relative multiples.
Price-to-Earnings Ratio
-2.4x
Price-to-Sales Ratio
39.5x
Price-to-Book Ratio
10.5x
EV / EBITDA
-2.3x
Dividend Yield
0%
Profitability Pulse
Follow margin structure and return ratios that benchmark execution quality and capital efficiency.
Growth Momentum
Gauge the trajectory of revenue, earnings, and free cash flow expansion to understand durability.
Cash & Balance Sheet
Monitor liquidity, leverage, and free cash flow capacity that underpin resilience across cycles.
AlphaPilot quick take
• Abivax S.A. trades at $114.51 with a market footprint around $8.7B.
• Operating within Healthcare — Biotechnology offers instant peer context.
• Dashboard highlight: revenue growth at 133.5%, refreshed from the live fundamentals feed.
• Pivot into AlphaPilot deep dives to benchmark valuation, execution, and resilience.
Company profile
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Abivax S.A. (ABVX) stock FAQs
Quick answers sourced from live Financial Modeling Prep fundamentals and AlphaPilot portfolio guidance.
What is Abivax S.A. (ABVX) stock price today?
Abivax S.A. (ABVX) trades near $114.51 as of Dec 5, 2025, 9:00 PM. Quotes refresh throughout the trading day in USD via Financial Modeling Prep, which powers the AlphaPilot dashboard.
What is Abivax S.A.'s market capitalization?
Abivax S.A.'s equity is valued around $8.7B, based on the latest share price multiplied by shares outstanding reported to Financial Modeling Prep.
What is the 52-week range for Abivax S.A.?
Abivax S.A.'s 52-week range runs from $4.77 — $130.25. Comparing the current price to this band helps visualize positioning versus the past year's highs and lows.
How active is trading in Abivax S.A. stock?
Abivax S.A. most recently moved about 1.3M shares. Elevated volume often signals strong investor interest or fresh catalysts.
Does Abivax S.A. pay a dividend?
Abivax S.A. currently yields roughly 0%. Dividend yield divides the last 12 months of payouts by the latest share price, providing a quick income snapshot.
What is Abivax S.A.'s intraday trading range?
Abivax S.A. has traded between $109.10 — $115.12 so far today. Monitoring the intraday span highlights short-term volatility relative to the longer 52-week range.
Where does the Abivax S.A. stock data come from?
AlphaPilot sources quotes, fundamentals, and intraday chart data for Abivax S.A. from the Financial Modeling Prep institutional API. The summary page blends live pricing with fundamentals that refresh after every earnings release or regulatory filing.